Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jingquan Ji, Ming Feng, Xiaohong Niu, Xinyu Zhang & Yilei Wang. (2021) Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR). Bioengineered 12:1, pages 8057-8066.
Read now
Read now
Luigi Barrea, Carolina Di Somma, Giovanna Muscogiuri, Giovanni Tarantino, Gian Carlo Tenore, Francesco Orio, Annamaria Colao & Silvia Savastano. (2018) Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition 58:18, pages 3141-3158.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
Thor Chalmer, Thomas P Almdal, Tina Vilsbøll & Filip K Knop. (2015) Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. Expert Opinion on Drug Safety 14:1, pages 171-180.
Read now
Read now
Articles from other publishers (15)
Simon Kloock, Christian G. Ziegler & Ulrich Dischinger. (2023) Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. Pharmacology & Therapeutics 251, pages 108549.
Crossref
Crossref
Jong Youl Lee, Taehoon Park, Eunmi Hong, Reeju Amatya, Kyung-Ah Park, Young-Hoon Park, Kyoung Ah Min, Minki Jin, Sumi Lee, Seungmi Hwang, Gu Seob Roh & Meong Cheol Shin. (2020) Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity. Biomaterials 257, pages 120250.
Crossref
Crossref
Kyung-Ah Park, Zhen Jin, Jong Youl Lee, Hyeong Seok An, Eun Bee Choi, Kyung Eun Kim, Hyun Joo Shin, Eun Ae Jeong, Kyoung Ah Min, Meong Cheol Shin & Gu Seob Roh. (2020) Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Pharmaceutics 12:2, pages 159.
Crossref
Crossref
Ayumu Niida, Yoko Kanematsu-Yamaki, Tomoko Asakawa, Yoshimasa Ishimura, Hisashi Fujita, Kouta Matsumiya, Naoki Nishizawa, Yusuke Adachi, Taisuke Mochida, Kazue Tsuchimori, Mariko Yoneyama-Hirozane, Junichi Sakamoto, Hideki Hirabayashi, Hideo Fukui, Shiro Takekawa & Taiji Asami. (2018) Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives. Bioorganic & Medicinal Chemistry 26:3, pages 566-572.
Crossref
Crossref
Yuanyuan Xiao, Junfeng Han, Qianqian Wang, Yueqin Mao, Meilin Wei, Weiping Jia & Li Wei. (2017) A Novel Interacting Protein SERP1 Regulates the N‐Linked Glycosylation and Function of GLP‐1 Receptor in the Liver. Journal of Cellular Biochemistry 118:11, pages 3616-3626.
Crossref
Crossref
Dominic N. McBrayer & Yftah Tal-Gan. (2017) Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus. Drug Development Research 78:6, pages 292-299.
Crossref
Crossref
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
De-hua Yang, Cai-hong Zhou, Qing Liu & Ming-wei Wang. (2015) Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure. Acta Pharmacologica Sinica 36:9, pages 1033-1042.
Crossref
Crossref
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li & Shen Qu. (2015) Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. International Journal of Endocrinology 2015, pages 1-11.
Crossref
Crossref
Xing-Chun Wang. (2014) Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World Journal of Gastroenterology 20:40, pages 14821.
Crossref
Crossref
Udo Stauder, Diplom Enginee, Hina Elton, Alfred Penfornis & Steve Edelman. (2014) Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices. Journal of Diabetes Science and Technology 8:1, pages 123-131.
Crossref
Crossref
S Vasu, R C Moffett, J T McCluskey, M H Hamid, N Irwin & P R Flatt. (2013) Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. Gene Therapy 20:11, pages 1077-1084.
Crossref
Crossref
Lyn H. Jones & David A. Price. 2013.
45
96
.
Hannelouise Kissow, Bolette Hartmann, Jens Juul Holst, Niels-Erik Viby, Lærke Schmidt Hansen, Mette Marie Rosenkilde, Kristine Juul Hare & Steen Seier Poulsen. (2012) Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides 179:1-3, pages 91-100.
Crossref
Crossref
S. Vollert, N. Kaessner, A. Heuser, G. Hanauer, A. Dieckmann, D. Knaack, H. P. Kley, R. Beume & C. Weiss-Haljiti. (2012) The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia 55:10, pages 2779-2788.
Crossref
Crossref